Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel population-based case-control study design in which "cases" have incident second- or higher-order melanomas [multiple primary melanoma (MPM)] and "controls" have incident first primary melanoma [single primary melanoma (SPM)]. Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma.

Original publication

DOI

10.1158/1055-9965.EPI-06-0270

Type

Journal article

Journal

Cancer Epidemiol Biomarkers Prev

Publication Date

08/2006

Volume

15

Pages

1520 - 1525

Keywords

Aged, Australia, Canada, Case-Control Studies, Chromatography, High Pressure Liquid, Cyclin-Dependent Kinase Inhibitor p16, Exons, Female, Germ-Line Mutation, Humans, International Agencies, Introns, Italy, Male, Melanoma, Middle Aged, Neoplasms, Multiple Primary, Polymerase Chain Reaction, Polymorphism, Genetic, Skin Neoplasms, United States